StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors. - PubMed - NCBI
Cancer Med. 2017 Apr 3. doi: 10.1002/cam4.1037. [Epub ahead of print]
StrandAdvantage test for early-line and advanced-stage treatment decisions in solid tumors.
Sen M1,2,
Katragadda S1,
Ravichandran A1,
Deshpande G1,
Parulekar M1,
Nayanala S1,
Vittal V1,
Shen W3,
Phooi Nee Yong M3,
Jacob J1,
Parchuru S1,2,
Dhanuskodi K1,2,
Eyring K3,
Agrawal P1,
Agarwal S1,
Shanmugam A1,
Gupta S1,
Vishwanath D1,2,
Kumari K1,2,
Hariharan AK1,2,
Balaji SA1,2,
Liang Q3,
Robolledo B3,
Gauribidanur Raghavendrachar V1,
Oomer Farooque M1,
Buresh CJ4,
Ramamoorthy P3,
Bahadur U1,
Subramanian K1,
Hariharan R1,
Veeramachaneni V1,
Sankaran S1,
Gupta V1,2.
Abstract
Comprehensive genetic profiling of tumors using next-generation sequencing (NGS) is gaining acceptance for guiding treatment decisions in cancer care. We designed a cancer profiling test combining both deep sequencing and immunohistochemistry (IHC) of relevant cancer targets to aid therapy choices in both standard-of-care (SOC) and advanced-stage treatments for solid tumors. The SOC report is provided in a short turnaround time for four tumors, namely lung, breast, colon, and melanoma, followed by an investigational report. For other tumor types, an investigational report is provided. The NGS assay reports single-nucleotide variants (SNVs), copy number variations (CNVs), and translocations in 152 cancer-related genes. The tissue-specific IHC tests include routine and less common markers associated with drugs used in SOC settings. We describe the standardization, validation, and clinical utility of the StrandAdvantage test (SA test) using more than 250 solid tumor formalin-fixed paraffin-embedded (FFPE) samples and control cell line samples. The NGS test showed high reproducibility and accuracy of >99%. The test provided relevant clinical information for SOC treatment as well as more information related to investigational options and clinical trials for >95% of advanced-stage patients. In conclusion, the SA test comprising a robust and accurate NGS assay combined with clinically relevant IHC tests can detect somatic changes of clinical significance for strategic cancer management in all the stages. © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
KEYWORDS:
Clinical utility; immunohistochemistry; next-generation sequencing; solid tumors; standard-of-care therapy
No hay comentarios:
Publicar un comentario